Aspire Biopharma Holdings, Inc. (ASBP)
| Market Cap | 906.01K -100.0% |
| Revenue (ttm) | 34,555 |
| Net Income | -11.76M |
| EPS | -145.02 |
| Shares Out | 167.47K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,206 |
| Open | 5.61 |
| Previous Close | 5.59 |
| Day's Range | 5.30 - 5.63 |
| 52-Week Range | 3.31 - 1,050.36 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About ASBP
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing form... [Read more]
Financial Performance
Financial StatementsNews
Aspire Biopharma Holdings Inc trading halted, news pending
19:50 EDT Aspire Biopharma (ASBP) Holdings Inc trading halted, news pending
Aspire Biopharma to effect 1-for-30 reverse stock split
Aspire Biopharma (ASBP) will effect a one-for-thirty reverse stock split of its common stock, par value $0.0001 per share, that will become effective on May 11, 2026, at 12:01 AM…
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today an...
Aspire Biopharma announces $5M share repurchase plan
Aspire Biopharma (ASBP) Holdings announced that its Board of Directors has authorized the repurchase of up to $5M of the Company’s common stock
Aspire Biopharma Announces $5.0 Million Share Repurchase Program
ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug deli...
Aspire Biopharma closes final tranche of $21M private placement
Aspire Biopharma (ASBP) closed the second and final tranche of the private placement announced on February 11 for the purchase and sale of 26,250 shares of Series A Convertible Preferred…
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS) LOI to acquire DCS, a leading global automotive sup...
Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run
Aspire Biopharma (ASBP) announced that elite ultra-marathoner and BUZZ BOMB Global Brand Ambassador Ashley Paulson will attempt to shatter the female world record for the fastest 100-mile treadmill ru...
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
Elite Ultra-Marathoner targets her second World Record in two months following historic Ultra Jackpot 100 Win ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:...
Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M
Aspire Biopharma (ASBP) Holdings entered into a Letter of Intent to acquire Dura Driver Control Systems, a designer and manufacturer of automotive driver control systems that also apply to other…
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug deli...
Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest
Aspire Biopharma (ASBP), wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic sales and marketing brokerage agreement with Interwest Brokerage. This partnership is designed to sc...
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Interwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience Channels ESTERO, FL / ACCESS Newswire / April 15, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire...
Aspire Biopharma subsidiary signs retail distribution agreement with TruLife
Aspire Biopharma (ASBP), its wholly owned subsidiary Buzz Bomb Caffeine Company, and TruLife Distribution have concluded an agreement under which TruLife will manage and coordinate the sales, distribu...
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels ESTERO, FL / ACCESS Newswire / March 19, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ...
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran Jo...
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health...
Aspire Biopharma launches BUZZ BOMB Covenience Store Pack
Aspire Biopharma (ASBP) Holdings is expanding its retail footprint with the launch of the BUZZ BOMB Convenience Store Pack. The lineup includes the newly designed six-count “Fruit Blast” package conta...
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Convenient Size at the Convenience Store ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffei...
Aspire Biopharma, Microsize partner for sublingual alprazolam formulation
Aspire Biopharma (ASBP) announced a strategic partnership with Microsize. Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active ...
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulatio...
Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint
Aspire Biopharma (ASBP) announced a “massive” expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company. The company said, “The initiati...
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS...
Aspire Biopharma regains compliance with Nasdaq listing requirements
Aspire Biopharma (ASBP) Holdings received a notification letter from The Nasdaq Stock Market confirming that the Company has regained compliance with the minimum stockholders’ equity threshold of $2.5...
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed Aspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings...